PharmAla Scores $100M+ Deal with Jupiter Neurosciences

PharmAla Biotech Holdings has partnered with Jupiter Neurosciences in a major deal granting Jupiter exclusive rights to PharmAla's lead drug candidate, ALA-002, in the United States. This agreement could be worth over $100 million through upfront payments and royalties. The partnership allows PharmAla to focus on its global strategy while providing Jupiter with a promising asset in the mental health treatment market.

#PharmAla #JupiterNeurosciences #DrugDeal #MentalHealth #Biotech #ALA002 #Pharmaceuticals #Partnership

Видео PharmAla Scores $100M+ Deal with Jupiter Neurosciences канала Don’t Blink News